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Abstract
Background: Reverse transcription PCR (RT-PCR) is widely recognized to be the gold standard method
for quantifying gene expression. Studies using RT-PCR technology as a discovery tool have historically
been limited to relatively small gene sets compared to other gene expression platforms such as
microarrays. We have recently shown that TaqMan® RT-PCR can be scaled up to profile expression for
192 genes in fixed paraffin-embedded (FPE) clinical study tumor specimens. This technology has also been
used to develop and commercialize a widely used clinical test for breast cancer prognosis and prediction,
the Onco typeDX™ assay. A similar need exists in colon cancer for a test that provides information on
the likelihood of disease recurrence in colon cancer (prognosis) and the likelihood of tumor response to
standard chemotherapy regimens (prediction). We have now scaled our RT-PCR assay to efficiently
screen 761 biomarkers across hundreds of patient samples and applied this process to biomarker
discovery in colon cancer. This screening strategy remains attractive due to the inherent advantages of
maintaining platform consistency from discovery through clinical application.
Results: RNA was extracted from formalin fixed paraffin embedded (FPE) tissue, as old as 28 years, from
354 patients enrolled in NSABP C-01 and C-02 colon cancer studies. Multiplexed reverse transcription
reactions were performed using a gene specific primer pool containing 761 unique primers. PCR was
performed as independent TaqMan®  reactions for each candidate gene. Hierarchal clustering
demonstrates that genes expected to co-express form obvious, distinct and in certain cases very tightly
correlated clusters, validating the reliability of this technical approach to biomarker discovery.
Conclusion: We have developed a high throughput, quantitatively precise multi-analyte gene expression
platform for biomarker discovery that approaches low density DNA arrays in numbers of genes analyzed
while maintaining the high specificity, sensitivity and reproducibility that are characteristics of RT-PCR.
Biomarkers discovered using this approach can be transferred to a clinical reference laboratory setting
without having to re-validate the assay on a second technology platform.
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Background
Over the last decade, many studies have applied gene
expression analysis to identify biomarkers for prognostic
and/or predictive information in relation to human dis-
ease [1-4]. RNA for these studies has come from either fro-
zen or formalin fixed paraffin embedded (FPE) tissue.
RNA from frozen tissues is generally regarded as the most
desirable for molecular assays, since if collected correctly
it is generally intact and can be analyzed by a wide variety
of standard molecular biology techniques. However, FPE
tissue is the most widely available source of tumor tissue
as it is the product of standard tissue processing proce-
dures followed by surgical pathology laboratories. It is
clear that RNA obtained from FPE tissue is not full length
and the extent of degradation increases with storage time
[5]. Therefore, it is generally considered to be challenging
to extract RNA from archival FPE tissue for analysis by
standard molecular biology techniques.
With the development of automated liquid handling and
DNA microarrays, high throughput screening using hun-
dreds of samples and hundreds or thousands of genes has
become routine in many laboratories. DNA microarrays
offer the advantage of simultaneously assessing the rela-
tive expression level of thousands of genes with a rela-
tively small amount of starting RNA. However, DNA
microarray measurements are limited in dynamic range,
specificity and reproducibility, leading to high false posi-
tive and false negative biomarker discovery rates. As cur-
rently configured, DNA microarray technology also
requires high quality RNA. Alternatively, reverse-tran-
scription polymerase chain reaction (RT-PCR) technology
offers the advantages of high accuracy and reproducibility,
and precise quantitation over a wide dynamic range. To
overcome the issue of fragmented RNA in FPE tissue spec-
imens, assays can be optimized for short amplicons so the
RNA from FPE tissue can be successfully analyzed [5].
It has been suggested that there is a bottleneck in scaling
up TaqMan® RT-PCR using archival FPE samples to ana-
lyze beyond 30 genes [6]. On the contrary, we demon-
strated that TaqMan® RT-PCR biomarker screening using
FPE samples is not necessarily limited to small candidate
gene sets and have performed studies with up to 192
genes [5,7,8]. Using this technology we developed and
commercialized a 21 gene panel that predicts the likeli-
hood of cancer recurrence in early stage breast cancer
patients [9]. We have now scaled our TaqMan® RT-PCR
screening process to assay 768 wells of data per patient
sample. Here we describe the methodology that was used
to identify prognostic biomarkers in stage II/III colon can-
cer [10].
In this paper we report the use of this high throughput,
highly parallel TaqMan® RT-PCR process to screen RNA
extracted from colon cancer FPE clinical trial specimens
(NSABP C01 and C02 studies). We focused on selecting
candidate genes known to be involved in pathways related
to colon cancer and genes from published expression pro-
filing data sets relating to colon cancer prognosis and
response to therapy. Our results indicate that this
approach yields high quality expression data that can be
used for simultaneous evaluation of hundreds of candi-
date genes in defined cohorts of patients to identify prog-
nostic and predictive colon cancer biomarkers.
Results
Large scale multiplexed, gene-specific reverse 
transcription
FPE RNA is largely fragmented, making it a poor substrate
for poly-dT primed reverse transcription. Random prim-
ing in combination with poly-dT priming has proven to
be somewhat more successful for generating cDNA from
FPE RNA [6,11]. However, with highly fragmented RNA,
even random priming does not yield satisfactory RT-PCR
data [see Additional file 1], as compared to that obtained
with in tact RNA [see Additional file 2]. We therefore
chose to maximize assay sensitivity by using gene specific
priming for each target sequence included in the RT-PCR
screening panel. To evaluate the quality and consistency
of cDNA from this complex reverse transcription reaction,
we compared the expression values resulting from 8
smaller reverse primer pools (each containing 94 to 96
primers) to those from the single pool with all of the
primers combined. In every case, cDNA from multiplexed
RT reactions was combined with PCR master mix and dis-
tributed into 384 well plates with each well containing the
primers and probe for 1 gene assay. High quality commer-
cial RNA (Universal RNA, Stratagene, La Jolla, CA.) was
used as the template for this evaluation. The resulting data
are shown in Figure 1. Each priming condition was
repeated twice and the mean CT values were plotted. The
mean CTvalues were very similar: CT = 29.40 versus CT =
28.98 for the small and large gene-specific primer (GSP)
pools, respectively. Additionally, the Pearson's correlation
for these two priming methods was 0.98. The median dif-
ference between priming methods was 0.4 CT units. The
large majority of assays (97.5%) had a CT difference less
than 2. For 2 of the assays which had a CT difference
greater than 2, this could be accounted for by 1 failed reac-
tion (CT = 40). The priming efficiency for all other assays
where alternative priming lead to a CT difference greater
than 2 appears to be reproducible so the result may be
accounted for by cross-priming events in the more com-
plex GSP pool.
While measuring the realistic limit of multiplexed RT-
priming in FPE RNA we did not want the data compli-
cated by biological variability contributed by individual
samples. We therefore created a sample consisting ofBMC Genomics 2007, 8:279 http://www.biomedcentral.com/1471-2164/8/279
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pooled FPE RNA that represented a range of high and low
expression values across the gene panel and reflected the
quality of samples that would be used in the gene identi-
fication study. This was done by pooling 36 breast FPE
RNA samples from tumor blocks over 10 years old. Two of
the 8 primer sub-pools were selected at random to verify
that the priming reaction remained consistent as the RNA
template type changed from a high quality sample to a
highly fragmented sample. The results, shown in Figure 2,
indicate that the reaction using FPE RNA as a template was
consistent with that seen for the high quality commercial
RNA. The Pearson's correlation was 0.95 and the mean CT
values obtained for the entire gene panel were almost
identical: CT = 31.84 versus CT = 31.79 using the small
and large gene-specific primer (GSP) pools, respectively.
The average raw CT obtained with the FPE RNA is higher
than that obtained with the high quality RNA. This is
expected since the FPE RNA is highly fragmented resulting
in fewer available targets for priming [5]. Although this
shift does result in FPE samples being somewhat skewed
toward the upper end of the assay dynamic range, typi-
cally at least a 2000 fold range in expression can still be
reliably measured for most genes before reaching the
assay limit of quantitation [12].
Once we confirmed the high complexity priming reaction
was working consistently in FPET RNA, we prepared a
gene specific primer pool containing 761 unique reverse
primers for the biomarker discovery study using NSABP
C01 and C02 clinical trial specimens.
Sample exclusion
To be included in the final study analysis, samples had to
pass pathology, clinical and laboratory data QC require-
ments. To meet pathology acceptance criteria, a minimum
of 5% of the tissue present in each sample was required to
be invasive cancer cells. All samples were dissected to
enrich tumor tissue and minimize non-tumor elements.
RNA was extracted from 354 FPE tissues cut from the
NSABP C01/C02 clinical study samples (archived from
1977–1983) [13,14]. All samples yielded RNA using the
semi-automated extraction process described below, how-
ever a total of 38 samples yielded less than the 1069 ng
Table 1: Sample exclusion criteria
Number excluded Percent excluded Remaining samples
Samples extracted N/A 0 354
Insufficient RNA -38 10.7% 316
Incomplete sample data -4 1.1% 312
Unsatisfactory qPCR -21 5.9% 291
Pathologically ineligble -10 2.8% 281
Clinically ineligble -11 3.1% 270
Total in final dataset 76.3% 270
Samples were excluded on the basis of several different categories. Various acceptance criteria were applied to the dataset. The table shows how 
many samples were excluded from the final dataset based on each category. There were 354 samples extracted and the final evaluable data set was 
270.
Effect of increasing priming complexity in reverse transcrip- tion using high quality RNA template Figure 1
Effect of increasing priming complexity in reverse 
transcription using high quality RNA template. Eight 
gene specific primer (GSP) pools each containing from 94 to 
96 unique primers were used to prime separate RT-PCR 
reactions with high quality commercial RNA template. These 
8 GSP pools were then combined to make a single GSP pool 
that was used to prime one RT-PCR reaction using the same 
template RNA. Both priming methods were performed twice 
and the average CT value for each gene was determined for 
this analysis. The solid line represents the least squares line 
fit and the dashed line represents the line of concordance.
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RNA required to ensure a final concentration of 1 ng/assay
well. We performed RT-PCR on 23 of these samples, but
none of these yielded acceptable RT-PCR data. Of the 306
samples taken through RT-PCR with the standard RNA
load, 21 (< 7%) were excluded from analysis due to unac-
ceptable RT-PCR data. Although the precise age of each
excluded block was not available, it is reasonable to
assume that the samples with unacceptable RT-PCR data
may have been from the oldest blocks [5]. After other pre-
specified exclusion criteria were applied, (pathological
and clinical ineligibility), the final number of evaluable
patients was 270. Table 1 provides a detailed breakdown
of all excluded samples. It should be noted that the overall
exclusion rate in this study is higher than we have experi-
enced in other studies and is very likely related to the age
of these samples, which is the oldest set we have analyzed.
Process throughput
Using a semi-automated extraction process, two lab tech-
nicians extracted RNA from 48 samples per day. Paraffin
was removed from the tissue manually with xylene, fol-
lowed by ethanol washes. After a proteinase K digestion
and phenol-chloroform purification, the remaining RNA
extraction steps were performed on an automated liquid
handler using a plate-based protocol. The purified RNA
was then quantified using an automated RiboGreen fluo-
rescence assay (Invitrogen, Carlsbad, CA.). The resulting
files containing the RNA quantification data were auto-
matically collected by the laboratory information man-
agement system (LIMS). The LIMS used those data to
generate an RNA concentration normalization work-list,
which was then executed by an automated liquid handler
during the reverse transcription reaction assembly proce-
dure. The reverse transcription reaction was completed
using an MJ Research thermocycler (Bio-Rad, Hercules,
CA). Finally, quantitative PCR reactions were assembled
at a rate of 64 plates (32 patient samples) per day. All
automated liquid handlers were obtained from Tecan
(TECAN Schweiz AG, Männedorf, Switzerland). This sys-
tem yielded a total of 24,576 real time quantitative PCR
reactions to be performed per day using four ABI PRISM
7900 HT instruments (Applied Biosystems, Foster City,
CA.).
Process reproducibility
Process reproducibility was monitored throughout the
study. Two Tecan Genesis liquid handling robots were
used to assemble plates for 335 patient samples over a
period of five weeks, for a total of 670 assay plates (this
includes samples run with an RNA concentration of less
than 1 ng/assay well). Given the large scale of the project
and the number of potential sources of variability, we
monitored the process performance and reagent stability
throughout the duration of the study. This was done by
using a single RNA reference sample made by pooling
RNA extracted from 80 FPE colon specimens (block age
ranging from 3 years – 6 years). As described previously, a
pooled FPE sample was selected as a reference RNA since
it more representative of a typical study sample than com-
mercially available RNA, yet sufficiently abundant to pro-
vide a stable reference baseline throughout the study
period. This sample was analyzed 3 times on the same ABI
7900 HT instrument to set a baseline reference profile for
the study genes and then was assayed at intervals through-
out the duration of the study. Figure 3 shows boxplots of
the averaged expression values of all 761 genes over time
for the reference sample. The baseline data (3 runs) and
all 8 repeat analyses done during the 5 weeks of the study
are shown. The outer fence of 3*IQR (Inter Quartile
Effect of increasing priming complexity reverse transcription  using FPE tissue RNA template Figure 2
Effect of increasing priming complexity reverse tran-
scription using FPE tissue RNA template. Eight GSP 
pools containing from 94 to 96 unique primers were pre-
pared. Two pools were selected at random to prime sepa-
rate RT-PCR reactions using RNA from FPE tissue. The 8 
GSP pools were then combined to make a single GSP pool 
that was used to prime one RT-PCR reaction using the same 
FPE RNA template. The data therefore represents concord-
ance between primings for the subset of gene assays repre-
sented with those two GSP pools. Both priming methods 
were performed twice and the average CT values determined 
for this analysis. The solid line represents the least squares 
line fit and the dashed line represents the line of concord-
ance.
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Boxplots for reference sample CT distributions of the 761 genes at time points throughout the study Figure 3
Boxplots for reference sample CT distributions of the 761 genes at time points throughout the study. These 
boxplots show averaged expression values of all 761 genes over the duration of the study. The bottom edge of the box repre-
sents the 25th percentile of the data while the top edge of the boxplot represents the 75th percentile. The line inside the box 
represents the 50th percentile of the data or the median and the symbol + represents the mean. The distance between the 25th 
and 75th percentiles is defined as the Inter Quartile Range (IQR). A whisker extends from the upper edge of the box to the 
largest value that is inside a distance of 1.5*IQR. Similarly, a whisker extends from the lower edge of the box to the smallest 
values inside a distance of 1.5*IQR. Observations outside the fences of 1.5*IQR are marked by a square. The first boxplot rep-
resents data from the 3 assay repeats used to set a baseline, all other boxplots represent a single assay run. Overall, the CT dis-
tributions of the 761 genes assayed in the reference sample were stable throughout the study.
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Range) was used to flag outliers. These data demonstrate
that assay reagents and the assay processes remained sta-
ble throughout the study period. This measurement has
been repeated for this sample during subsequent studies
and continues to give consistently reproducible results
(data not shown).
Figure 4 shows the same reference sample data with the
associated standard deviations (SD) obtained for all 11
data points for each gene assay, plotted against the mean
CT expression value. The majority of assays (737 out of
761) showed a SD less than 1.0. The genes indicated by
symbol "∆"are those where mispipetting by the robot
resulted in a single empty well. These wells were given a
CT value of zero. The gene indicated by symbol "" was
caused by a single spurious failed reaction well which was
assigned a CT value of 40.
The four ABI PRISM 7900 HT machines used for the study
underwent qualification to meet internal performance
specifications prior to use in clinical studies. Figure 5 rep-
resents typical data from a comparison (raw CT values) of
the reference sample on two different machines. The Pear-
son's correlation is 0.97. The variance in RT-PCR data
increases as the CT  value increases and the assay
approaches its "limit of quantitification" (LOQ). This has
been described in detail elsewhere [12] and is consistent
with the variance observed in this study.
Two 384 well plates were prepared per patient RNA spec-
imen to screen all 761 candidate marker genes. Assays
were randomly assigned between the two plates except for
reference genes which were present on both assay plates.
The average CT values for each plate pair were compared
and the data are illustrated in Figure 6. This graph demon-
Comparison of RT-PCR results for the reference RNA sam- ple assayed on two different machines Figure 5
Comparison of RT-PCR results for the reference 
RNA sample assayed on two different machines. Two 
separate RT-PCR reactions were set up and assayed on dif-
ferent ABI 7900 HT machines, using the reference RNA sam-
ple. The graph represents paired raw CT values for each of 
the 761 assays obtained from each of these two machines. 
The solid line represents the least squares line fit and the 
dashed line represents the line of concordance.
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Average CT value versus standard deviation for the reference  RNA sample Figure 4
Average CT value versus standard deviation for the 
reference RNA sample. Plotted here is the average CT 
value for each gene versus the standard deviation (SD) for 
each gene from a total of 11 assay runs. The "" symbols 
represent genes where a single run had an empty assay well 
and was assigned a value of zero. The "" symbol represents 
a gene where one out of the 11 runs resulted in a spurious 
"failed" well and was assigned a CT value of 40. These data 
show great consistency over the study.
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strates that plates from the same patient give consistent
raw mean CT values prior to reference normalization. The
one outlier specimen was repeated, and on repeat fell into
alignment with the other plate results. It should be noted
that Figure 6 represents all patient samples taken through
RT-PCR, including the 23 samples run with less than 1 ng/
well input RNA. These specimens, which had high average
plate CT values were excluded from the final study analysis
due to unsatisfactory RT-PCR data.
Expression data normalization
Although the two assay plates for each patient RNA were
run on the same ABI Prism 7900 instrument to minimize
process variability, data from each sample had to be inter-
nally normalized to allow all study specimens to be com-
pared without being confounded by relative variability in
RNA quality, quantity or process variability. This was
accomplished by subtracting the averaged expression val-
ues from 6 reference genes (CLTC, NEDD8, RPLPO,
RPS13, UBB, UBC) from the expression values for each
gene in each sample. This method has previously been
shown to effectively compensate for variability associated
with RNA degradation in FPE material of different ages
and qualities [5]. Normalization genes were chosen on
the basis of low expression variation among patient sam-
ples, robust CT signals (CT < 35) and lack of association
with clinical outcome. As part of our quality control and
acceptance criteria, the average expression CT value for the
6 reference genes for each patient sample had to be less
than 35. Within the final evaluable dataset of 270 patient
samples, the average reference signal was 29.5 CT (SD =
1.39 CT) with the lowest observed reference signal at 33.7
CT, indicating good overall signal response and relative
invariance in reference genes among patients.
Comparison of paired raw CT values for reference normaliza- tion gene RPLPO for all patients Figure 7
Comparison of paired raw CT values for reference 
normalization gene RPLPO for all patients. RPLPO 
was one of 6 normalization genes. The graph shown here 
represents the paired raw CT values for RPLPO on both 
assay plates for all patients in the study. Paired plates for each 
patient sample were assayed on the same ABI 7900 HT 
machine. The solid line represents the least squares line fit 
and the dashed line represents the line of concordance.
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Comparison of paired whole plate average CT values for all  patients Figure 6
Comparison of paired whole plate average CT values 
for all patients. Expression analysis for 761 unique genes 
required each patient RNA sample to be divided between 
two 384 well plates. Shown here is the average raw CT value 
for all wells of data obtained for plate one plotted against the 
average raw CT obtained for plate two, for each patient. The 
patient sample which appears to be an outlier was re-assayed 
through RT-PCR and on repeat analysis, fell into alignment 
with the other samples. The solid line represents the least 
squares line fit and the dashed line represents the line of con-
cordance.
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Proliferation Figure 8
Proliferation. Gene groups identified by clustering analysis. Clustering analysis was performed using the 1-Pearson's R 
distance and unweighted pair-group average amalgamation method. Clustering was performed using all 761 genes. Figures 8-13 
represent selected clusters from the entire 761 gene dendogram.
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Epithelial/secreted Figure 9
Epithelial/secreted. Gene groups identified by clustering analysis. Clustering analysis was performed using the 1-Pear-
son's R distance and unweighted pair-group average amalgamation method. Clustering was performed using all 761 genes. Fig-
ures 8-13 represent selected clusters from the entire 761 gene dendogram.
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A high degree of reproducibility was seen for these refer-
ence genes, as shown by the RPLPO example, in Figure 7.
Because this gene was assayed on both QPCR plates for
each patient sample, a direct comparison of CT values
between plates could be made. The intra-specimen Pear-
son's correlation for RPLPO was 0.98.
Gene groups and genes correlated to recurrence free 
interval (RFI) in colon cancer
As an indication of the robustness of this high complexity
assay we sought to identify co-expressed groups of genes,
that are plausible based on known biological pathways.
Unsupervised cluster analysis was performed on the final
sample set using all 761 genes, resulting in several distinct
clusters representing known biological pathways. Figures
8, 9, 10, 11, 12, 13 display sub-clusters observed among
the 761 genes. We identified the following gene groups
and pathways: cell cycle and proliferation, epithelial
markers (or products secreted by epithelial cells), focal
adhesion, stromal response, early response and immune/
interferon inducible genes. The most highly correlated
gene set from among these groups was the stromal
response gene group, where the 1-Pearson's distance for
26 genes was less than 0.5. Within this group are many
genes that encode extracellular matrix (ECM) proteins and
regulators thereof – a signature similar to that seen during
wound healing [15]. There is also a very high concordance
in gene expression between p16ink4 and p14arf. This is to
be expected since these are alternative transcripts of the
same gene and the primer probe set used for p16ink4 also
amplifies the p14arf variant. Additionally, correlations
among genes within families were observed; for example,
CDX1 and CDX2 (Pearsons correlation = 0.67), FUT3 and
FUT6 (Pearsons correlation = 0.59), AREG and EREG
(Pearsons correlation = 0.73), HSP1A1 and HSP1AB
(Pearsons correlation = 0.44).
After data quality control and reference normalization,
approximately 19% of the cancer related genes tested in
this study were found to have a significant (p < 0.05) cor-
relation with Recurrence Free Interval (RFI) by univariate
regression analysis [10]. Approximately one quarter of
these genes would be expected to be false positives [10].
While a large number of candidate genes showed signifi-
cant correlations with clinical outcome (on both the raw
and normalized CT measurements), the average reference
signal was shown not to be correlated with disease recur-
rence.
Discussion
The development of a clinically validated test that could
determine the risk of recurrence or death from stage II/III
colon cancer and the likelihood of benefit from standard
chemotherapy regimens is highly desirable but complex.
The process begins with biomarker discovery and ends
with a clinical validation study with prospectively defined
endpoints. Since the method by which an mRNA species
is measured will have a profound effect on the success of
such a validation study, it is important to characterize and
maintain the assay's performance, particularly its repro-
ducibility and quantitative precision. Consequently, we
have adopted RT-PCR, the most robust gene expression
method available for gene discovery studies. Although
nearly 150 genes were found to be significantly related to
RFI in this study, some markers will prove to be false pos-
itives and true markers will vary in how robustly they cor-
relate with outcome. It is therefore important to evaluate
the candidate genes identified here by conducting further
independent studies to identify truly useful disease
biomarkers. Only after consistent association with clinical
outcomes in multiple independent studies should genes
be considered for inclusion in an assay used to make clin-
ical decisions. Employing a single technology consistently
throughout biomarker discovery and into clinical testing
has the advantage of reducing the time required to fully
validate and commercialize a multi-gene clinical decision-
making tool.
RT-PCR is often carried out using oligo-dT priming to
generically reverse transcribe mRNA from the polyA tail.
However, this technique is unsuccessful with degraded
RNA, such as that extracted from FPE tissue. We have pre-
viously shown that RT-PCR using gene-specific priming
can be successfully applied to FPE tissue as old as 30 years
[5]. As described here, we have now increased the scale of
screening using this technique, to 761 genes. We further
demonstrate that gene specific priming for 761 assays can
be successfully combined into a single RT reaction that
results in precise, sensitive and reproducible quantitative
PCR for biomarker discovery.
DNA microarrays are a popular technology for biomarker
discovery because one can quickly examine the expression
of hundreds or thousands of genes. RT-PCR has often
been subsequently used to verify the results of microarray
data, since it offers much higher sensitivity, specificity,
reproducibility and a greater quantitative dynamic range.
The present results demonstrate that RT-PCR can also be
applied to highly parallel gene expression analysis if
robotic processes and assay miniaturization are used. We
were able to extract and quantify RNA and generate
expression data for 761 unique assays for more than 300
patients in less than 5 weeks.
While screening these patient specimens, it was important
to monitor potential sources of variability such as primer
and probe stability and gene specific primer pool stability.
We used an FPE colon RNA pool as a reference sample and
generated a baseline CT value for each of the 761 assays.
This FPE colon RNA pool reference sample was thenBMC Genomics 2007, 8:279 http://www.biomedcentral.com/1471-2164/8/279
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Focal adhesion Figure 10
Focal adhesion. Gene groups identified by clustering analysis. Clustering analysis was performed using the 1-Pearson's 
R distance and unweighted pair-group average amalgamation method. Clustering was performed using all 761 genes. Figures 8-
13 represent selected clusters from the entire 761 gene dendogram.
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Stromal response Figure 11
Stromal response. Gene groups identified by clustering analysis. Clustering analysis was performed using the 1-Pear-
son's R distance and unweighted pair-group average amalgamation method. Clustering was performed using all 761 genes. Fig-
ures 8-13 represent selected clusters from the entire 761 gene dendogram.
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Early response Figure 12
Early response. Gene groups identified by clustering analysis. Clustering analysis was performed using the 1-Pearson's 
R distance and unweighted pair-group average amalgamation method. Clustering was performed using all 761 genes. Figures 8-
13 represent selected clusters from the entire 761 gene dendogram.
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Immune/interferon-inducible genes Figure 13
Immune/interferon-inducible genes. Gene groups identified by clustering analysis. Clustering analysis was per-
formed using the 1-Pearson's R distance and unweighted pair-group average amalgamation method. Clustering was performed 
using all 761 genes. Figures 8-13 represent selected clusters from the entire 761 gene dendogram.
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included during reverse transcription with every patient
sample batch and used to monitor process stability
throughout the study. Over the 5 week period, variability
within the reference sample remained low, indicating that
all patient samples were being analyzed with a stable
assay process. Analysis of one of the reference genes,
RPLPO, which was assayed on both plates for every
patient sample, also highlighted the internal consistency
of the process throughout the study.
The robustness of this technology is evidenced by results
from hierarchical clustering of all 761 genes which identi-
fied known pathways and gene group clusters that one
would expect to be co-expressed. One of the largest was a
"stromal response" gene group containing genes that are
associated with wound healing and are thought to be rep-
resentative of fibroblast activation, or the 'stromal
response' within tumor stroma. Stromal response is
becoming increasingly recognized as a marker of invasion
and poor clinical outcome in several different classes of
solid tumors [16-20]. A number of genes within this
group encode proteins that compose or regulate extracel-
lular matrix including BGN, SPARC, CTGF, THBS, VIM,
and COL1A1. Several focal adhesion and actin-binding
protein genes grouped together to form another distinct
cluster, including CALD1, TAGLN, TLN, MYH11, MYLK
and CNN. Because MYH11, MYLK and CNN are genes
specific to muscle, they could represent a myofibroblast
(MF) signature. The myofibroblast cell type has been
implicated as a driver of tumor progression [21]. Another
cluster might be called an "epithelial/secreted" gene
group; within this group are genes known to be markers
of epithelial cells or code products secreted by them, such
as SERPINB5 (maspin), KRP19, KLK10 and LAMB2. A
cluster containing GBP1, GBP2, G1P2, IFIT, CD8A, CD8A,
HLA-DRPB1 and CXCR4 represents an immune/inter-
feron-inducible group. Another group contains genes that
represent acute response to stimuli, or "early response"
genes such as EGR1, EGR3, RhoB, FOS and NR4A. An
inflammatory response gene group was also identified,
containing genes such as ICAM1, IL1B, IL-8, IL6, OSM
and S100A8. A small group of intestinal specific genes
such as MUC2, MUC5B, pS2 (TFF1) and TFF3 are also
highly correlated in expression. Lastly, it was gratifying to
see that the expression of CDH1 and CAPN1 were corre-
lated with one another (Pearson's correlation = 0.48)
since CAPN1 cleaves CDH1 [22]. Given the biological
connection between these genes, one may have expected
this correlation to be higher – possibly indicating specific
post-translational control mechanisms may have a role in
defining steady state protein levels.
The aim of this study was to identify gene biomarkers that
predict recurrence-free interval in patients with Stage II
and Stage III colon cancer. Approximately 19% of the 761
genes showed a significant (p < 0.05) association with RFI
by univariate Cox proportional hazards regression analy-
sis. It is highly unlikely that any one gene will be able to
predict clinical outcome or response to therapy to the
extent that it will be useful to oncologists. A successful
diagnostic tool is much more likely to consist of a panel
of genes and an algorithm weighting and combining each
gene contribution into one value that defines the unique
risk of recurrence and potential for therapeutic response
in each patient. This concept is supported by the observa-
tion that several different biological pathways were shown
to be associated with RFI in this study.
Conclusion
We have demonstrated that RT-PCR can be scaled to ena-
ble studies testing hundreds of candidate genes for
biomarker discovery in hundreds of archival FPE cancer
biopsy specimens. Analysis of the data from this study has
shown it to be biologically plausible and consistent with
known pathways and gene groups identified to be impor-
tant in cancer. We are applying this technology to colon
cancer with the aim of developing a predictive and prog-
nostic clinical test for patients with this disease.
Methods
Tissue specimens
Archival colon tumor FPE tissue blocks were provided by
the NSABP from both the C01 "A Clinical Trial To Evalu-
ate Postoperative Immunotherapy And Postoperative Sys-
temic Chemotherapy In The Management Of Resectable
Colon Cancer" and C-02 "A Protocol To Evaluate The
Postoperative Portal Vein Infusion Of 5-Fluorouracil And
Heparin In Adenocarcinoma Of The Colon" clinical trials.
Patients were enrolled in these trials between 1977–1983.
Samples used in this study are representative of the gen-
eral study populations for both trials.
Tissue sectioning and macrodissection
Histotechnologists wore gloves at all times when han-
dling tissue blocks. Before and after each block was sec-
tioned, any debris was removed from the microtome with
a disposable cotton swab or brush. All appliances (brush,
forceps, knife, knife holder base) were wiped with an
RNase Zap wipe followed by a soft cloth wetted with de-
ionized water. A tissue floatation bath was used to help
eliminate wrinkles and distortions in sections being
mounted to glass microscope slides. When dissection was
required to remove significant non-tumor elements, a rep-
resentative H&E stained slide was used as a guide to mark
tumor and non-tumor portions of three 10 micron
unstained slides. Tumor tissue was then scraped away
from the non tumor material and placed into an extrac-
tion tube. The tumor tissue from all 3 sections was placed
into the same tube.BMC Genomics 2007, 8:279 http://www.biomedcentral.com/1471-2164/8/279
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RNA extraction
RNA was extracted from the tumor-enriched portion of
three 10 micron sections per patient block. In order to
scale sample throughput to 48 samples/batch, the RNA
extraction procedure used a semi-automated method per-
formed on a TECAN robotic liquid handler (TECAN Sch-
weiz AG, Männedorf, Switzerland). The samples
originated in individual 1.5 ml Eppendorf tubes and par-
affin was removed by incubating with lab grade xylene for
5 minutes. Tissue was then pelleted by centrifugation at
room temperature (+18°C to +25°C) for 5 minutes at
approximately 14,000 RPM. The xylene was removed and
the procedure repeated. The tissue pellet was washed by
inverting several times with 200 proof ethyl alcohol and
again pelleting by centrifugation at room temperature.
The ethyl alcohol wash step was repeated. Immediately
prior to adding Proteinase K, samples were inspected for
residual alcohol; if any alcohol was visible, it was aspi-
rated without disturbing the tissue pellet. Proteinase K
digestion was performed using reagents from the Master-
Pure® Purification kit (Epicentre, Madison, WI). Samples
were incubated at +65°C for 2 hr with Proteinase K. Pro-
tein and genomic DNA were removed by manual addition
of an equal volume of acid-phenol: chloroform and the
removal of the upper aqueous phase after centrifugation
for 5 minutes at approximately 10,000 RPM. Samples
tubes were transferred to a TECAN liquid handler where
purification was completed using the mirVana™ RNA
purification kit (Ambion, Austin, Texas) on a 96 well glass
fiber filter plate. Purification was followed by DNase I
treatment on the same 96 well filter plate.
RNA quantitation
RNA was quantified using the RiboGreen fluorescence
method as described by the kit manufacturer (Invitrogen,
Carlsbad, CA.).
Candidate gene selection
Candidate genes were obtained from published gene
expression profiling data relating to colon cancer progno-
sis and response to therapy, biological pathways known to
be important in cancer [23-28] and suggestions by our
collaborators at the NSABP. The full gene list, accession
numbers and associated primer and probe oligo
sequences are provided [see Additional file 3].
TaqMan® primer and probe design
The reference sequence for each gene included in the
study was obtained from the NCBI Entrez website. Taq-
Man® RT-PCR primers and probes were designed using an
automated in-house primer design module. The complete
list of assay primers and probes is shown in Additional file
3. Oligonucleotides were purchased from Biosearch Tech-
nologies Inc. (Novato, CA), Integrated DNA Technologies
(Coralville, IA) and Eurogentec (San Diego, CA). Dual
labeled TaqMan® probes had 5'FAM as a reporter and
either 3'BHQ-1 or 3'BHQ-2 as a quencher. Amplicon size
was limited to a maximum of 90 bp.
Reverse transcription
Reverse transcription was performed using the Omnis-
cript kit (Valencia, CA) for RT-PCR. For initial investiga-
tions, reverse primers (each at 100 µM) were collected
into sub-pools of 94–96 primers. An aliquot from each
sub-pool was added together to create the final GSP pool
(each primer at 100 nmol/L). For the clinical study,
reverse primers (each at 1 mM) were first collected in sub-
pools of 89–96 primers and tested for priming perform-
ance before being combined into a master 761 gene-spe-
cific primer pool (each primer at 1 µmol/L). For both the
initial investigations and the clinical study, each primer in
the RT reaction was at a concentration of 50 nmol. Our
standard procedure was to add RNA to the RT reaction at
12.5 ng/ul which equates to 1 ng/well (cDNA) for quanti-
tative PCR. In each case, the RT reaction was performed in
a single tube with the GSP pool (ie up to 761 reverse prim-
ers). The resulting cDNA was distributed equally among
the wells of a 384 well plate, and the appropriate forward
and reverse primer and probe were added to each assay
well.
TaqMan® gene expression analysis
For each patient sample, two 384-well plates were used.
Assays for 7 potential reference genes were included on
both plates, with all other gene assays randomly distrib-
uted in single assay wells. RT-PCR assays for three K-ras
gene mutations and one BRAF gene mutation were
included in the assay panel along with each correspond-
ing wild type allele assay. Therefore, 757 normal gene alle-
les were assayed and 4 mutant genes were assayed,
bringing the total number of unique assays to 761. Taq-
Man® RT-PCR was performed according to instructions of
the manufacturer, using Applied Biosystems Prism (ABI)
7900 HT instruments. Reactions were performed in a 5 µl
volume with cDNA equivalent to 1 ng total RNA. Final
primer and probe concentrations were 0.9 µmol/L (prim-
ers) and 0.2 µmol/L (probe). For the K-ras mutation
assays a blocker oligomer was added to the primer and
probe pool at a final concentration of 3.6 µmol/L (mutant
1) 3.6 µmol/L (mutant 2) and 12.95 µmol/L (mutant 3).
These blockers are added to inhibit amplification of the
non-mutant allele, permitting specific amplification of
the mutant allele. PCR cycling conditions were 95°C for
10 minutes for one cycle, 95°C for 20 seconds, and 60°C
for 45 seconds for 40 cycles. A reference sample (pooled
colon FPET RNA) was assayed throughout the study to
ensure reagent and process stability. As a negative control,
wells without any template were also assayed every two
weeks to ensure that no exogenous nucleic acid contami-
nations occurred.BMC Genomics 2007, 8:279 http://www.biomedcentral.com/1471-2164/8/279
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Unsupervised hierarchical clustering
The unsupervised hierarchical clustering of genes was per-
formed using 1-Pearson R as the distance measure for
gene expression and the un-weighted pair-group average
as the amalgamation method [29].
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